Table 1 Demographic and clinical characteristics of the study cohorts
|  | children (N = 32) | C + V+ (N = 27) | C + V- (N = 7) |  |
|---|---|---|---|---|
Age years -median (range)*1 | 11 (1–18) | 47 (19–68) | 46 (20–65) |  |
Female gender N (%) | 12 (37.5) | 17 (63) | 5 (71) | Â |
Time since COVID-19 Diagnosis (months)*2median (range) | 6 (1–15) | 12 (7–16) | 9 (5–12) |  |
COVID-19 Severity N (%) | ||||
Asyptomatic-Mild | 32 (100) | 25 (93) | 7 (100) | Â |
Severe | 0 | 1 (3.5) | 0 | Â |
Critical | 0 | 1 (3.5) | 0 | Â |
Time since last antigenic contact (months)*3 median (range) | 6 (1–15) | 5 (4–8) | 9 (5–12) |  |
Number of mRNA vaccinations | ||||
1Â N (%) | 0 | 19 (70) | 0 | Â |
2Â N (%) | 0 | 8 (30) | 0 | Â |
Number of antigenic contacts | 0 | 2 (2–3) | 1 |  |